Advertisement
U.S. markets close in 37 minutes
  • S&P 500

    4,604.01
    +18.42 (+0.40%)
     
  • Dow 30

    36,258.96
    +141.58 (+0.39%)
     
  • Nasdaq

    14,402.39
    +62.40 (+0.44%)
     
  • Russell 2000

    1,880.17
    +11.92 (+0.64%)
     
  • Crude Oil

    71.33
    +1.99 (+2.87%)
     
  • Gold

    2,017.10
    -29.30 (-1.43%)
     
  • Silver

    23.33
    -0.72 (-3.01%)
     
  • EUR/USD

    1.0765
    -0.0033 (-0.30%)
     
  • 10-Yr Bond

    4.2450
    +0.1160 (+2.81%)
     
  • GBP/USD

    1.2546
    -0.0047 (-0.37%)
     
  • USD/JPY

    144.9450
    +0.7540 (+0.52%)
     
  • Bitcoin USD

    44,010.54
    +740.00 (+1.71%)
     
  • CMC Crypto 200

    908.75
    +12.04 (+1.34%)
     
  • FTSE 100

    7,554.47
    +40.75 (+0.54%)
     
  • Nikkei 225

    32,307.86
    -550.45 (-1.68%)
     

ReShape Lifesciences® Announces Participation in the LD Micro Main Event XVI

ReShape Lifesciences Inc
ReShape Lifesciences Inc

IRVINE, Calif., Sept. 22, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Paul F. Hickey, President and Chief Executive Officer, and Tom Stankovich, Chief Financial Officer, will present a company overview on Tuesday, October 3, 2023 at 3:30 PM PT, at LD Micro’s 16th Annual Main Event, taking place October 3-5 at the Luxe Sunset Boulevard Hotel in Los Angeles. During the presentation, management will highlight the company’s next-generation, anatomy-sparing, Lap-Band® program and the nationwide, ReShapeCare™ virtual weight-management program.

ReShape Lifesciences’ management team will be available for one-on-one meetings during the conference. To register, please contact registration@ldmicro.com. To schedule a meeting with management outside of the conference, contact Michael Miller with Rx Communications at mmiller@rxir.com.

A live webcast and replay of the presentation will be available here.

About ReShape Lifesciences®
ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. ReShapeCare™ is a virtual weight-management program that supports lifestyle changes for all weight loss patients led by board-certified health coaches to help them keep the weight off over time. ReShape Marketplace™ is an online collection of quality wellness products curated for all consumers to help them achieve their health goals. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of Type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.

CONTACTS
ReShape Lifesciences Investor Contact:
Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com

Investor Relations Contact:
Rx Communications Group
Michael Miller
(917)-633-6086
mmiller@rxir.com


Advertisement